Physician profile
Michael Eugene Chismer
NPI 1194786087
$2,738.37
in general payments reported to CMS, 2019-2025
26 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.51 · 2020: $34.64 · 2021: $53.34 · 2022: $78.70 · 2023: $701 · 2024: $1,581 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $285.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $263.60 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $229.31 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $217.91 | 2023-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $216.23 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $210.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $147.70 | 2024 | |
| Madrigal Pharmaceuticals | $138.67 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $137.02 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $100.44 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.33 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $98.56 | 2021-2025 | Veozah, Ambisome |
| Exact Sciences Corporation | $89.06 | 2023-2024 | Cologuard Collection Kit |
| Pulmonx Corporation | $77.03 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Shield Therapeutics INC | $56.43 | 2023-2024 | Accrufer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53.98 | 2022-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $49.02 | 2022-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $46.80 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $45.43 | 2019-2024 | Xarelto |
| Dexcom, INC. | $39.22 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $38.83 | 2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $34.84 | 2024 | Voquezna |
| Tactile Systems Technology INC | $18.14 | 2025 | Nimbl, Flexitouch Plus |
| E.R. Squibb & Sons, L.L.C. | $16.01 | 2024 | Eliquis |
| Abbott Laboratories | $14.73 | 2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $13.92 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chismer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.